wherein each among R1 and R2 represents (C1-C6)-alkyl group optionally substituted with halogen atoms and so on; each among R3, R4 and R5 represents hydrogen atom, halogen atom and so on, either R3 and R4 in common with carbon atoms bound to them can form a carbocyclic or heterocyclic ring optionally having a substitute (substitutes); A represents -N(R7)(R8) and so on; ring B represents aryl group or heterocyclic residue; R6 represents hydrogen atom, halogen atom, (C1-C6)-alkyl group and so on; n means a whole number from 1 to 3, or its pharmaceutically acceptable salt. Proposed compounds elicit the selective and strong inhibitory effect on CETP activity and can be used as therapeutic or prophylactic agents against hyperlipidemia or arteriosclerosis. Also, the proposed compound can be used with other pharmaceutical agent or some pharmaceutical agents simultaneously against hyperlipidemia or arteriosclerosis. Invention provides the development of a pharmaceutical composition based on dibenzylamine compounds used in treatment or prophylaxis of hyperlipidemia or arteriosclerosis.;EFFECT: valuable medicinal properties of compound and pharmaceutical composition.;25 cl, 40 tbl, 174 ex"/>
公开/公告号RU2293078C2
专利类型
公开/公告日2007-02-10
原文格式PDF
申请/专利权人 DZHAPAN TOBAKKO INK.;
申请/专利号RU20040119546
发明设计人 MAEDA KIMIJA (JP);NAGAMORI KHIRONOBU (JP);NAKAMURA KHIROSI (JP);SINKAJ KHISASI (JP);SUZUKI JASUNORI (JP);TAKAKHASI DAJSUKE (JP);TANIGUTI TOSIO (JP);
申请日2003-08-29
分类号C07C229/46;A61K31/41;A61P3/06;A61P9/10;
国家 RU
入库时间 2022-08-21 20:30:42